UNSPSC 51172830: Hydrofluoric acid/sodium fluoride

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OR100. This VA Drug Class (OR100) classifies this compound as belonging to the group CARIOSTATICS, TOPICAL.

UNSPSC 51172830 Hydrofluoric acid/sodium fluoride is a Commodity code nominally designating chemical products, but the recent state and local procurement activity under this code reflects generic multi-source pharmaceuticals and over-the-counter (OTC) products rather than industrial chemicals. State and local governments are soliciting manufacturers to supply comprehensive pharmaceutical product lines through cooperative purchasing vehicles, with vendors required to provide detailed product specifications including National Drug Codes (NDC), SKUs, UPCs, strength, dosage form, and packaging configurations. Issuing bodies include state departments of administration and cooperative purchasing alliances administering contracts that span multiple participating jurisdictions. Vendors must maintain current Good Manufacturing Practices (cGMP) certification, comply with the Drug Supply Chain Security Act (DSCSA) and FDA requirements, and establish contractual relationships with authorized pharmaceutical wholesalers including AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC, with chargeback systems in place. Performance requirements include maintaining insurance coverage with commercial general liability of $5,000,000 per occurrence and network security and privacy liability of $2,000,000, and vendors face performance penalties ranging from $200 to $1,500 per violation for late reporting, missed onboarding timelines, or improper class-of-trade denials.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal (solicitation number S1070000015802) on January 20, 2026, with a response deadline of March 26, 2026, to establish multiple contracts for generic multi-source pharmaceuticals and OTC products for distribution across participating state and local government facilities including Oregon. Evaluation weights pricing heavily at 75 percent, with the remaining 25 percent distributed across fixed pricing (10 percent), compliance with administrative fee data format requirements (5 percent), electronic data interchange capability (5 percent), and agreement to a 3 percent administrative fee (5 percent). Awards will take effect July 1, 2026, with a two-year initial contract term and optional extensions at MMCAP's discretion, and MMCAP reserves the right to make sole, dual, or multi-awards based on therapeutic considerations, product availability, patient safety, and member-specific needs. All products must be available in the marketplace by May 15, 2026, and must possess expiration dates of at least one year from manufacture with a minimum six-month shelf life.